Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale

Paris-based Jeito Capital announced Jeito II, a €1B (~$1.2B) fund on April 8, 2026, for mid- to late-stage European biopharma companies.

The problem this fund is attacking

European biopharma has high-quality science but often raises U.S. growth capital, moving HQs and tax bases across the Atlantic. Fund vehicles of this size allow quality European clinical-stage assets to scale without forced relocation.

Why this is a live problem now

• AI-driven drug discovery has compressed pre-clinical timelines, increasing the number of candidates seeking growth capital.
• European universities and spin-outs remain strong sources of differentiated biology.
• Government-backed capital (Bpifrance and others) continues to anchor European biopharma.

Competitive map

• Sofinnova Partners, Forbion, Medicxi, Kurma Partners.
• U.S. firms with EU practices: Arch Venture Partners, OrbiMed, RA Capital.
• Corporate venture arms of pharma giants.

Market signal (the number to remember)

• €1B dedicated to mid-to-late stage European biopharma — in one fund — is unusual and consequential.

Practical takeaway (operator + investor)

1. Biotech operators: European late-stage capital is a viable alternative to relocating for a Nasdaq path.
2. Investors: EU biopharma funds are competing for a finite set of clinical programs; fund pacing and syndication matter.

Sources

1. Yutori Scouts fund tracker: https://scouts.yutori.com/8b847103-9d57-41bd-b907-94108a38ecfe